Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Open Label, Randomized, Controlled Study to Evaluate Safety and Immunogenicity of VPM1002 in Comparison With BCG in HIV-unexposed, BCG Naive Newborn Infants in South Africa

NCT01479972 is registered in ClinicalTrials.gov with Serum Life Science Europe GmbH as lead sponsor.

NCT NCT01479972
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01479972 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Open Label, Randomized, Controlled Study to Evaluate Safety and Immunogenicity of VPM1002 in Comparison With BCG in HIV-unexposed, BCG Naive Newborn Infants in South Africa
Lead sponsor
Serum Life Science Europe GmbH
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2011
Completion date
November 30, 2012
Enrollment
48 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

tuberculosis